ClinicalTrials.gg
RecruitingNCT07547904Updated Nov 17, 2026

Clinical Performance of Bioactive Bulk-Fill in Class II Restorations

An interventional study of Activa BioACTIVE Bulk Flow and Filtek Z250 in Dental Caries, sponsored by Bezmialem Vakif University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Bezmialem Vakif University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 17, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 130 studies in Dental Caries with a site in Turkey — 24 open to participants now, 40 under way, none of them phase 3. Dental Caries · Turkey.

Planned enrollment
79th of 94
34 · median 60
Started
2026
with 14 others
No phase
91 of 130
20 open now
Primary completion
2027-11
later than 36 of 39 live
Registered
109th of 130
by date
Lead sponsor
8 of 130
Bezmialem Vakif University

Among the 130 studies in Dental Caries with a site in Turkey, this one is the 79th largest by planned enrollment of the 94 interventional ones that give a count, is one of 15 that started in 2026, is one of 91 with no phase, reaches primary completion later than 36 of the 39 other live ones, and was the 109th registered.

Dental Caries

1,176 studies on the registry are indexed under Dental Caries; 209 are open to participants now.

Browse Dental Caries studies →

Open to participants now

24 of the 130 studies in Dental Caries with a site in Turkey are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 86 Dental Caries studies recruiting now, 18 (21%) set no upper age limit and 66 (77%) stop at 75 or younger; 60 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies in Dental Caries with a site in Turkey, or all of them as a file.
02

Study summary

This prospective split-mouth clinical study aims to compare the clinical performance of a bioactive bulk-fill composite with a conventional microhybrid composite in Class II posterior restorations. In each participant, two comparable Class II cavities will be treated using different restorative approaches. In the experimental condition, a bioactive bulk-fill composite (Activa BioACTIVE Bulk Flow) will be placed at the gingival base and covered with a microhybrid composite (Filtek Z250). In the control condition, restorations will be completed entirely with the microhybrid composite (Filtek Z250).

Clinical performance will be evaluated according to FDI World Dental Federation criteria at baseline, 6 months, and 12 months. Primary outcomes include marginal adaptation, retention, and overall clinical success of the restorations. Secondary outcomes include surface properties and marginal staining.

The split-mouth design allows direct intra-individual comparison, thereby minimizing inter-individual variability and increasing the reliability of the findings. The results of this study are expected to provide evidence on the effectiveness of bioactive bulk-fill composites in improving the clinical performance of posterior restorations.

03

Conditions studied

  • Dental Caries

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged between 18 and 50 years
  • Patients requiring at least two comparable Class II restorations in posterior teeth
  • Good general and oral health
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Patients with systemic diseases affecting oral health
  • Pregnant or lactating women
  • Poor oral hygiene or high caries risk
  • Teeth with pulp involvement or periapical pathology
  • History of allergy to dental materials used in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Bioactive Bulk-Fill Composite

    Bioactive bulk-fill composite (Activa BioACTIVE Bulk Flow) applied at the gingival base and covered with microhybrid composite (Filtek Z250).

    Device: Activa BioACTIVE Bulk Flow

  • Active comparator
    Conventional Composite

    Restorations performed entirely using microhybrid composite (Filtek Z250).

    Device: Filtek Z250

Interventions

  • DeviceActiva BioACTIVE Bulk Flow

    Bioactive bulk-fill composite material used at the gingival base in Class II restorations.

  • DeviceFiltek Z250

    Conventional microhybrid composite used for full restoration in Class II cavities.

06

What researchers measure

Primary outcomes

  1. Clinical performance of restorations (FDI criteria)

    Evaluation of restorations according to FDI criteria including marginal adaptation, retention, and overall clinical success.

    Time frame: Baseline, 6 months, and 12 months

Secondary outcomes

  1. Marginal discoloration and surface properties

    Assessment of marginal staining and surface characteristics of restorations based on FDI criteria.

    Time frame: Baseline, 6 months, and 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Nov 2027, 21 months after the start.

Of 470 non-industry interventional studies with no phase under Dental Caries, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 21 months is above that.

Counting every sponsor, half of 503 studies reached it within 15 months; a quarter within 7 and three quarters within 29.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jun 2027 → Nov 2027 and completion Aug 2027 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2026
First posted
Apr 23, 2026
StartActual
Feb 5, 2026
Primary completionEst.
Nov 30, 2027was Jun 2027
CompletionEst.
Jan 30, 2028was Aug 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2027→Nov 30, 2027
Nov 17, 2026
Study completion
Aug 30, 2027→Jan 30, 2028
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Jun 30, 2027→Nov 30, 2027
    Study completion Aug 30, 2027→Jan 30, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07547904
Responsible party
Sponsor
First posted
Apr 23, 2026
Start date
Feb 5, 2026
Primary completion
Nov 30, 2027 (estimated)
Completion
Jan 30, 2028 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion